ALZN
vs
S&P 500
ALZN
S&P 500
Over the past 12 months, ALZN has underperformed S&P 500, delivering a return of -80% compared to the S&P 500's +14% growth.
Stocks Performance
ALZN vs S&P 500
Performance Gap
ALZN vs S&P 500
Performance By Year
ALZN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Alzamend Neuro Inc
Glance View
Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Tampa, Florida and currently employs 2 full-time employees. The company went IPO on 2021-06-15. The firm's pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.